The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2012;(1): 36‑41

Read: 24561 times

Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2012;(1):36‑41. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. Zhu Y., Pandya B.J., Choi H.K. Comorbidities of gout and hyperuricemia in the US general population — the National Health and Nutrition Examination Survey 2007—2008. Am J Med (In press).
  2. Choi H.K., Atkinson K., Karlson E.W., Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005;165:742—748.
  3. Choi H.K., Mount D.B., Reginato A.M. Pathogenesis of gout. Ann Intern Med 2005;143:499—516.
  4. Wyngaarden J.B., Kelley W.N. Gout and hyperuricemia. Grune & Stratton, 1976.
  5. Prebis J.W., Gruskin A.B., Polinsky M.S., Baluarte H.J. Uric acid in childhood essential hypertension. J Pediatr 1981;98:702—707.
  6. Messerli F.H., Frohlich E.D., Dreslinski G.R., et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980;93:817—821.
  7. Comparative effects of ticrynafen and hydrochlorothiazide in the treatment of hypertension. N Engl J Med 1979;301:293—297.
  8. Reyes A.J. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17:397—414.
  9. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981;2:539—543.
  10. Ruilope L.M., Kirwan B.A., de Brouwer S., et al. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens 2007;25:1711—1718.
  11. Chanard J., Toupance O., Lavaud S., et al. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003;18:2147—2153.
  12. Burnier M., Waeber B., Brunner H.R. Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects. J Hypertens Suppl 1995;13:S23—28.
  13. Burnier M., Roch-Ramel F., Brunner H.R. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787—1790.
  14. Shahinfar S., Simpson R.L., Carides A.D., et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999;56:1879—1885.
  15. Hoieggen A., Alderman M.H., Kjeldsen S.E., et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041—1049.
  16. Alderman M., Aiyer K.J. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369—379.
  17. Hayashi K., Ozawa Y., Fujiwara K., et al. Role of actions of calcium antagonists on efferent arterioles—with special references to glomerular hypertension. Am J Nephrol 2003;23:229—244.
  18. Wurzner G., Gerster J.C., Chiolero A., et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855—1860.
  19. Minghelli G., Seydoux C., Goy J.J., Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268—271.
  20. Hamada T., Hisatome I., Kinugasa Y., et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793—797.
  21. Elliott W.J., Calhoun D.A., DeLucca P.T., et al. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001;23:1166—1179.
  22. Gonzalez-Ortiz M., Mora-Martinez J.M., Martinez-Abundis E., Balcazar-Munoz BR. Effect of valsartan on renal handling of uric acid in healthy subjects. J Nephrol 2000;13:126—128.
  23. Monterroso V.H., Rodriguez Chavez V., Carbajal E.T., et al. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Adv Ther 2000;17:117—131.
  24. Muller P., Flesch G., de Gasparo M., et al. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 1997;52:441—449.
  25. Manolis A.J., Grossman E., Jelakovic B., et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000;22:1186—1203.
  26. Burgess E.D., Buckley S. Acute natriuretic effect of telmisartan in hypertensive patients. Am J Hypertens 2000;13:183A.
  27. McIntyre M., MacFadyen R.J., Meredith P.A., et al. Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men. J Cardiovasc Pharmacol 1996;28:101—106.
  28. Puig J.G., Torres R., Ruilope L.M. AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens Suppl 2002;20:S29—31.
  29. Puig J.G., Mateos F., Buno A., et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033—1039.
  30. Ilson B.E., Martin D.E., Boike S.C., Jorkasky D.K. The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol 1998;38:437—441.
  31. Enomoto A., Kimura H., Chairoungdua A., et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447—452.
  32. Hamada T., Ichida K., Hosoyamada M., et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008;21:1157—1162.
  33. Leary W.P., Reyes A.J., Wynne R.D., van der Byl K. Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects. J Int Med Res 1990;18:120—141.
  34. Hunter D.J., York M., Chaisson C.E., et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006;33:1341—1345.
  35. Andersen G.S. Atenolol versus bendroflumethiazide in middle-aged and elderly hypertensives. Acta Med Scand 1985;218:165—172.
  36. Pedersen O.L., Jacobsen F.K., Stengaard-Pedersen K. Renal uric acid handling is not affected by beta-adrenoceptor blockade in normotensive subjects. Eur J Clin Pharmacol 1985;28:223—224.
  37. Malini P.L., Strocchi E., Cervi V., Ambrosioni E. The metabolic effects of enalapril. Clin Exp Hypertens A 1987;9:675—679.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.